Multi-omics Mendelian Randomization Data for IBS Drug Target Discovery

Huiwen Ke published a dataset on figshare in May 2026 containing results from a druggable genome-wide Mendelian randomization analysis for irritable bowel syndrome. The analysis integrated summary statistics from a large IBS GWAS with 53,400 cases and 433,201 controls and comprehensive blood eQTL data. It identified eight genes with potential causal associations, with EP300 and P2RY14 emerging as the most promising candidate drug targets.

Use Cases

• Prioritizing genetically validated drug targets for IBS based on integrated GWAS and eQTL data.
• Evaluating potential on-target adverse effects using phenome-wide association study (PheWAS) results.
• Predicting therapeutic compounds for candidate targets using molecular docking predictions.
• Validating causal associations for drug targets with colocalization analysis.
• Supporting drug repurposing efforts by identifying existing compounds that bind to target proteins.

Strengths

• Analysis integrates summary statistics from a large IBS GWAS with 53,400 cases and 433,201 controls.
• Evaluated causal effects of 5,642 potential druggable protein-coding genes.
• Results were validated with colocalization analysis and PheWAS for adverse effect assessment.
• Dataset is openly available under a CC-BY-4.0 license.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect methodological bias inherent to the Mendelian randomization and eQTL integration approach.

Provenance

Source

figshare

Collection Method

Systematic druggable genome-wide Mendelian randomization analysis integrating GWAS and eQTL data.

Freshness

Last updated 2026-05-18 22:02:55; freshness should be verified.